产品
编 号：F481479
分子式：C18H30N2O4S
分子量：370.51
分子式：C18H30N2O4S
分子量：370.51
产品类型
规格
价格
是否有货
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价
结构图
CAS No: 854056-07-8
产品详情
生物活性：
Ropivacaine mesylate is a long-acting amide local anaesthetic agent for a spinal block and effectively blocks neuropathic pain. Ropivacaine blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibressup>. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel)?TREK-1?with an IC50?of 402.7 μM in COS-7 cell's membrane.
体内研究：
Epidural administration of Ropivacaine mesylate effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury.Ropivacaine mesylate inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC).Ropivacaine mesylate prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats.Ropivacaine mesylate inhibits pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs.Animal Model:Adult Sprague-Dawley rats (300-400g)
Dosage:1 μM
Administration:Infusion (added to the perfusate reservoir)
Result:Attenuated pressure-dependent increases in filtration coefficient (Kf).
Ropivacaine mesylate is a long-acting amide local anaesthetic agent for a spinal block and effectively blocks neuropathic pain. Ropivacaine blocks impulse conduction via reversible inhibition of?sodium ion influx?in nerve fibressup>. Ropivacaine is also an inhibitor of K2P (two-pore domain potassium channel)?TREK-1?with an IC50?of 402.7 μM in COS-7 cell's membrane.
体内研究：
Epidural administration of Ropivacaine mesylate effectively blocks neuropathic pain (both mechanical allodynia and heat hyperalgesia) without induction of analgesic tolerance and significantly delays the development of neuropathic pain produced by peripheral nerve injury.Ropivacaine mesylate inhibits pressure-induced increases in filtration coefficient (Kf) without affecting pulmonary artery pressure (Ppa), pulmonary capillary pressures (Ppc), and zonal characteristics (ZC).Ropivacaine mesylate prevents pressure-induced lung edema and associated hyperpermeability as evidence by maintaining PaO2, lung wet-to-dry ratio and plasma volume in levels similar to sham rats.Ropivacaine mesylate inhibits pressure-induced NO production as evidenced by decreased lung nitro-tyrosine content when compared to hypertensive lungs.Animal Model:Adult Sprague-Dawley rats (300-400g)
Dosage:1 μM
Administration:Infusion (added to the perfusate reservoir)
Result:Attenuated pressure-dependent increases in filtration coefficient (Kf).
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备